1. Home
  2. EDAP vs ATHA Comparison

EDAP vs ATHA Comparison

Compare EDAP & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EDAP
  • ATHA
  • Stock Information
  • Founded
  • EDAP 1979
  • ATHA 2011
  • Country
  • EDAP France
  • ATHA United States
  • Employees
  • EDAP N/A
  • ATHA N/A
  • Industry
  • EDAP Biotechnology: Electromedical & Electrotherapeutic Apparatus
  • ATHA Medicinal Chemicals and Botanical Products
  • Sector
  • EDAP Health Care
  • ATHA Health Care
  • Exchange
  • EDAP Nasdaq
  • ATHA Nasdaq
  • Market Cap
  • EDAP 113.2M
  • ATHA 93.5M
  • IPO Year
  • EDAP 1997
  • ATHA 2020
  • Fundamental
  • Price
  • EDAP $2.65
  • ATHA $0.45
  • Analyst Decision
  • EDAP Strong Buy
  • ATHA Buy
  • Analyst Count
  • EDAP 2
  • ATHA 4
  • Target Price
  • EDAP $14.00
  • ATHA $11.25
  • AVG Volume (30 Days)
  • EDAP 60.8K
  • ATHA 504.5K
  • Earning Date
  • EDAP 11-07-2024
  • ATHA 11-07-2024
  • Dividend Yield
  • EDAP N/A
  • ATHA N/A
  • EPS Growth
  • EDAP N/A
  • ATHA N/A
  • EPS
  • EDAP N/A
  • ATHA N/A
  • Revenue
  • EDAP $66,481,303.00
  • ATHA N/A
  • Revenue This Year
  • EDAP $9.53
  • ATHA N/A
  • Revenue Next Year
  • EDAP $15.87
  • ATHA N/A
  • P/E Ratio
  • EDAP N/A
  • ATHA N/A
  • Revenue Growth
  • EDAP 8.79
  • ATHA N/A
  • 52 Week Low
  • EDAP $2.45
  • ATHA $0.41
  • 52 Week High
  • EDAP $8.50
  • ATHA $4.30
  • Technical
  • Relative Strength Index (RSI)
  • EDAP 36.17
  • ATHA 23.77
  • Support Level
  • EDAP $2.56
  • ATHA $0.41
  • Resistance Level
  • EDAP $2.82
  • ATHA $0.47
  • Average True Range (ATR)
  • EDAP 0.17
  • ATHA 0.02
  • MACD
  • EDAP 0.04
  • ATHA 0.08
  • Stochastic Oscillator
  • EDAP 37.04
  • ATHA 53.28

About EDAP EDAP TMS S.A.

Edap TMS SA is a holding company operating in three divisions namely, HIFU (High-Intensity Focused Ultrasound), ESWL (Extracorporeal ShockWave Lithotripsy), and Distribution. The HIFU division develops, manufactures, and markets devices for the invasive destruction of certain types of tumors using HIFU technology. It markets three HIFU devices: the Ablatherm, Ablatherm Fusion, and the Focal One. The ESWL division is engaged in the manufacturing, marketing, and servicing of its installed base of Sonolith range of lithotripters. The Distribution division markets products that are complementary to its global activity such as lasers, micro-ultrasound systems, and other medical products from third parties. Its geographical segments are Asia, France, United States, and Others.

About ATHA Athira Pharma Inc.

Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.

Share on Social Networks: